SML2102
GSK256066
别名:
6-({3-[(Dimethylamino)carbonyl]phenyl}sulfonyl)-8-methyl-4-{[3-(methoxy)phenyl]amino}-3-quinolinecarboxamide, 6-[[3-[(Dimethylamino)carbonyl]phenyl]sulfonyl]-4-[(3-methoxyphenyl)amino]-8-methyl-3-quinolinecarboxamide, GSK 256066, GSK-256066
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C27H26N4O5S
化学文摘社编号:
分子量:
518.58
UNSPSC Code:
51111800
MDL number:
NACRES:
NA.21
Assay:
≥97% (HPLC)
Form:
powder
assay
≥97% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
−20°C
SMILES string
[S](=O)(=O)(c4cc(ccc4)C(=O)N(C)C)c1cc2c([nH]cc([c]2=Nc3cc(ccc3)OC)C(=O)N)c(c1)C
InChI
1S/C27H26N4O5S/c1-16-11-21(37(34,35)20-10-5-7-17(12-20)27(33)31(2)3)14-22-24(16)29-15-23(26(28)32)25(22)30-18-8-6-9-19(13-18)36-4/h5-15H,1-4H3,(H2,28,32)(H,29,30)
InChI key
JFHROPTYMMSOLG-UHFFFAOYSA-N
Biochem/physiol Actions
GSK256066 is a reversible and cAMP-competitive phosphodiesterase 4 (PDE4) inhibitor that targets all PDE4 subtypes with high affinity (IC50 = 53.7 pM against 2 nM [3H]-rolipram for binding HRBS in rat brain cytosol), potency and selectivity (pIC50 ≥11.31/11.5/11.42/11.94 against PDE4A/B/C/D vs. pIC50 = 5.73/5.92/5.93/5.39/5.28/8.11 against PDE1/2/3/5/6/7 by SPA assays). GSK256066 effectively inhibits LPS-induced TNFα production from human whole blood and isolated PBMCs (pIC50 = 126 and 10 pM, respectively) in vitro and acute pulmonary neutrophilia in rats in vivo (ED50 = 1.1 μg/kg, administered intratracheally 2 hrs priror to LPS). GSK256066 is shown to be more potent than Cilomilast (SB-207499) and Roflumilast in both cell-free and cell-based assays.
Highly potent and selective phosphodiesterase 4 (PDE4) inhibitor that inhibits LPS-induced inflammatory response both in cultures and in rats in vivo.
存储类别
11 - Combustible Solids
wgk
WGK 3
法规信息
新产品
此项目有
Michael D Woodrow et al.
Bioorganic & medicinal chemistry letters, 19(17), 5261-5265 (2009-08-07)
Crystallography driven optimisation of a lead derived from similarity searching of the GSK compound collection resulted in the discovery of quinoline-3-carboxamides as highly potent and selective inhibitors of phosphodiesterase 4B. This series has been optimized to GSK256066, a potent PDE4B
Cathy J Tralau-Stewart et al.
The Journal of pharmacology and experimental therapeutics, 337(1), 145-154 (2011-01-06)
Oral phosphodiesterase (PDE) 4 inhibitors such as roflumilast have established the potential of PDE4 inhibition for the treatment of respiratory diseases. However, PDE4 inhibitor efficacy is limited by mechanism-related side effects such as emesis and nausea. Delivering the inhibitor by
Anthony T Nials et al.
The Journal of pharmacology and experimental therapeutics, 337(1), 137-144 (2011-01-06)
Oral phosphodiesterase (PDE) 4 inhibitors have demonstrated clinical efficacy in chronic obstructive pulmonary disease and asthma. Preclinical and clinical investigation of inhaled PDE4 inhibitors is ongoing. 6-({3-[(Dimethylamino)carbonyl]phenyl}sulfonyl)-8-methyl-4-{[3-methyloxy)phenyl]amino}-3-quinolinecarboxamide (GSK256066) is an exceptionally high-affinity and selective inhibitor of PDE4 designed for inhaled
全球贸易项目编号
| 货号 | GTIN |
|---|---|
| SML2102-5MG | 04061835502516 |
| SML2102-25MG | 04061835502509 |